Menu

Search

  |   Business

Menu

  |   Business

Search

Eli Lilly Partner With Amazon for Home Delivery of Its Zepbound Weight Loss Drug

Amazon will now deliver Eli Lilly's weight loss drug Zepbound.

Eli Lilly and Company, a pharmaceutical company based in Indianapolis, Indiana, revealed it has teamed up with Amazon Pharmacy to help deliver its Zepbound weight loss drug and other medicines straight to customers' homes.

It struck a partnership deal with the online pharmacy subsidiary of Amazon Inc. just four months after obtaining the required regulatory approval to sell its diabetes treatment under a different name and category: weight loss.

Lilly's Weight Loss Treatment

According to CBS News, Eli Lilly's Tirzepatide drug, currently sold as a Mounjaro brand for diabetes, is now on the market under the new name Zepbound. It is also advertised as a weight-loss medication administered using an injection pen.

The company reportedly started selling Zepbound earlier this year. The drugs are directly sold to patients. Patients consult with doctors and obtain prescriptions from digital pharmacies, and the drugs are delivered to them.

Amazon Pharmacy Added as Home Delivery Option

Its partnership with Amazon's pharmacy unit allows patients and customers to obtain their medications quickly. In addition to Amazon Pharmacy, Eli Lilly delivers drugs to its customers via Truepill.

"Lilly has selected Amazon Pharmacy as a dispensing pharmacy option, allowing patients to receive fast, free delivery of medications and 24/7 access to clinical pharmacists," Dr. Vin Gupta, Amazon Pharmacy's chief medical officer, said in a press release. "To help patients being treated for diabetes, obesity, and migraine, Amazon Pharmacy is now offering home delivery of select medications through LillyDirect."

Dr. Gupta added, "Lilly has selected Amazon Pharmacy to serve as a third-party dispensing provider for LillyDirect Pharmacy Solutions, delivering prescribed Lilly medications directly to a patient's home."

Photo by: James Yarema/Unsplash

  • Market Data
Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.